iBio (IBIO) Stock Rockets On 3D Bioprinting News

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is running for the top in the market this morning, trading on gains of well over 50%. The gains come after the company issued a late press release yesterday announcing 3D bioprinting news. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Climbs On 3D Bioprinting News

iBio issued a press release early this morning announcing that it has entered into a Master Services Agreement with Lung Biotechnology PBC. Lung Biotechnology PBC is a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR).

Under the terms of the agreement, the two companies will work to produce recombinant human collagen based bioink for 3D bioprinted organ transplants. IBIO said that it will collaborate with Lung Biotechnology PBC in an effort to scale-up production of rhCollagen in tobacco plants using its FastPharming system.

In the release, the company said that the initial work under the gareement will surround the development of a scalable purification process for rhCollagen tailored to the biofabrication of lung scaffolds. The company will also focus on cGMP supply of the material for clinical trials.

With an expectation that there will be strong commercial demand of these bioinks, the company expects that additional projects will focus on process optimization and capacity expansion. At this stage, the company’s Factory Solution capabilities will come into play.

In a statement, Robert B. Kay, CEO and Chairman at IBIO, had the following to offer:

Recent scientific breakthroughs in the emerging field of 3D bioprinting have captured headlines worldwide. The decision by United Therapeutics to work with iBio for the production of rhCollagen bioinks in our FastPharming System provides yet another opportunity to demonstrate the strength of our platform, which has already been proven in the manufacture of monoclonal antibodies, growth factors, fusion proteins, virus-like particles, and other biologics. We’re looking forward to helping United Therapeutics to successfully address the critical shortage of transplantable lungs and other organs.

This News Is Huge

There’s a good reason that investors are so excited about iBio and the news that was just released. After all, according to Reportlinker, the global organ transplant market will grow to be worth $29 billion by the year 2019.

Should iBio and United Therapeutics develop a way to essentially 3D print organs that can be transplanted into humans, it could take a decent share of this market. Afterall, this would make organs more available to those on waiting lists, creating compelling opportunities for patients, the company and its investors.

Considering the fact that IBIO trades with a market cap that’s sub-$15 million, if it were to tackle just 1% of the transplant market, the $290 million in annual revenue would be a significant value add for the company and all involved.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big News

Join our free mailing list below to receive real-time alerts!

Subscribe Today!

* indicates required

1 thought on “iBio (IBIO) Stock Rockets On 3D Bioprinting News”

  1. United Therapeutics licensed from CollPlant Biotechnologies Inc!!!
    You didnt wrote nothing about Collplant…. I bought CLGN shares.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.